Editorial Guidelines

To ensure the integrity of all content produced by the Lymphoma Coalition (LC), a rigorous process has been put in place that entails the gathering and validation of information that is shared with the general public, its members, social media and the website. All content is validated prior to publication as described under Editorial Procedure.

LC has enlisted an Editorial Guidelines Committee made up of members of the LC Medical Advisory Board, LC members, pharmaceutical representatives and a member of the International Society of Nurses in Cancer Care. The committee offers feedback and guidance on publications, topics, and process and procedures.

Editorial Procedure

LC reviews up to 500 RSS feeds each week that focus on findings from clinical trials and medical research from peer-reviewed journals (e.g., Journal of Clinical Oncology, Blood) regulatory agencies (e.g., Food and Drug Administration, the National Comprehensive Cancer Network, European Society of Medical Oncology), conference proceedings (e.g., American Society of Hematology annual meeting, the American Society of Clinical Oncology annual meeting, European Hematology Association Congress, the International Conference on Malignant Lymphomas), clinical trial registries and general news media. The information is then divided between content development, the member Resource Library, newsletters and the website.

LC receives information from other sources, e.g., news releases issued by pharmaceutical companies, publications on single institution retrospective studies and while LC archives this information, LC does not use it as a single source of information.

All content for LC is developed by a healthcare writer under the guidance of the Cheif Executive Officer (CEO).

Content development entails reviewing research gathered by LC’s research coordinator as well as interviewing healthcare professionals, representatives from relevant healthcare organisations and LC members.

Any clinical or medical content developed by LC based solely on its own research is first reviewed by the CEO and then reviewed and approved by a member of LC’s medical advisory board or a medical professional involved in the development of the article prior to publication.

All other content developed is first reviewed by the CEO and then reviewed and approved by the respective organisation or parties involved prior to publication.

All articles are dated with the publication date.

Editorial Guidelines Committee

Brian Tomlinson, CancerCare®, USA
Pru Etcheverry, Leukaemia & Blood Cancer New Zealand
Fatima Scipione, Takeda Oncology
Chad Saward, Celgene
Dr. Laurie Sehn, British Columbia Cancer Agency
Dr. John Seymour, Peter MacCallum Cancer Centre, Australia
Janice Stewart, International Society of Nurses in Cancer Care

 

The purpose of this website is to help build our members global reach, provide accurate lymphoma facts and statistics, and improve awareness and understanding of lymphomas. This  site is intended for use by all members of the lymphoma community and the general public.

 

Website Content Editors:

Principal author:

Karen Van Rassel, CEO, Lymphoma Coalition

Other contributors:

Leonie Bedford, Medical Writer, Lymphoma Coaliion

David Burchett, Webmaster, Lymphoma Coalition

Jacob Hodara, Webmaster, Lymphoma Coalition

 

The last modification date of lymphomacoalition.org was August 26, 2016.

 

August 2016

 

Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1

IN THE NODE

Updates

 knowyoursubtype iconb   facebook2 twitter2 youtube1 Contact Us 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.